WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Forum: Aktien User: Summer.76

WuXi AppTech (02359) stellt klar, dass weder das Unternehmen noch seine Tochtergesellschaften in die „Unverified List“ des US-Handelsministeriums aufgenommen wurden https://m.jrj.com.cn/madapter/hk/2022/02/08151134306722.shtml

https://m.jrj.com.cn/madapter/hk/2022/02/15185534354811.shtml

https://m.jrj.com.cn/madapter/hk/2022/03/10151834808721.shtml

https://www.prnewswire.com/news-releases/wuxi-apptec-reports-strong-revenue-growth-in-2021-301508858.html

"WuXi AppTec plant den Aufbau eines neuen Standorts in Singapur, um globale Partner besser zu bedienen und Innovationen im Gesundheitswesen voranzutreiben" https://www.prnewswire.com/news-releases/wuxi-apptec-plans-to-build-a-new-site-in-singapore-better-serving-global-partners-and-advancing-healthcare-innovation-301588964.html

WuXi AppTec has stopped falling and turbulence, and biomedicine is still a popular track https://m.cn.investing.com/analysis/article-200469449

https://finance.sina.cn/hkstock/ggyw/2021-12-16/detail-ikyamrmy9275471.d.html?from=wap

Der CRO-Sektor beschleunigte seinen Rückgang am Nachmittag... https://finance.sina.cn/hkstock/ggyw/2021-12-15/detail-ikyakumx4292300.d.html?from=wap

https://www.biospectrumasia.com/news/40/19433/chinas-wuxi-sta-forms-strategic-partnership-with-coherent-biopharma.html

WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers https://www.prnewswire.com/news-releases/wuxi-atu-opens-new-facility-in-philadelphia-tripling-testing-capacity-to-support-global-customers-301423668.html New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry.

WuXi AppTec Reports Strong Third-Quarter 2021 Results https://www.wfmz.com/news/pr_newswire/pr_newswire_health/wuxi-apptec-reports-strong-third-quarter-2021-results/article_85e75845-d42f-50af-92e1-bd9c2ba6c87e.html

Chinese fund managers buy new-energy stocks and ditch tech giants, quarterly portfolio report shows https://www.scmp.com/business/markets/article/3154027/chinese-fund-managers-buy-new-energy-stocks-and-ditch-tech-giants • Sungrow Power Supply, WuXi AppTec and Shanxi Xinghuacun saw the biggest increases in holdings of fund managers in the third quarter • Total assets managed by China’s mutual funds increased 4 per cent quarter on quarter to US$3.7 trillion at the end of September ...

Fitch Upgrades WuXi AppTec's IDR to 'BBB'; Outlook Stable https://www.fitchratings.com/research/corporate-finance/fitch-upgrades-wuxi-apptec-idr-to-bbb-outlook-stable-25-10-2021

Lässt sich auch ohne die App lesen: Pharmaceutical stocks pay attention to growth confirmation  https://specialist.hket.com/article/3086579/%E3%80%90%E8%B4%8F%E9%9D%A2%E8%82%A1%E8%BF%BD%E8%B9%A4%E3%80%91%20%E9%86%AB%E8%97%A5%E8%82%A1%E7%95%99%E6%84%8F%20%20%20%E6%88%90%E9%95%B7%E6%80%A7%E7%A2%BA%E5%AE%9A%20%20%EF%BC%88%E9%99%84%E8%82%A1%E7%A5%A8%E6%8E%A8%E4%BB%8B%EF%BC%89%EF%BC%88%E7%AC%AC%E4%BA%8C%E7%89%88%EF%BC%89 In the medium term, the growth determined by the pharmaceutical sector will still be one of the main directions for investment in the entire market in 2022. October and even Q4 will be the best time to deploy the pharmaceutical sector. This research report will focus on the investment strategy of the pharmaceutical industry and recommend favorite stocks, such as WuXi AppTec (02359) , Cinda Bio (01801) , Ascent Pharmaceuticals (06855) and Rongchang Bio (09995), etc. It is also recommended to pay attention WuXi Biologics (02269) , Tigermed (03347), etc. The main reasons for the obvious signs of stabilization in the pharmaceutical sector: ...

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers https://www.prnewswire.com/news-releases/wuxi-atu-opens-new-manufacturing-facility-to-further-enhance-its-ctdmo-services-for-global-customers-301401893.html WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia. As its fourth manufacturing site worldwide, the new facility will supplement WuXi ATU's global footprint and will further join with other sites in the United States, United Kingdom and China to enable global customers with enhanced capacity and efficient services.  ...